-
Biocon Biologics Secures Market Entry Date For Yesafili, An Interchangeable Biosimilar To Eylea, In The U.S.
17 Apr 2025 12:23 GMT
… Federal Circuit (USCAFC) of patent US11084865 (‘865 patent) and the pending litigation … .gov/medwatch.
About Biocon Biologics Limited:
Biocon Biologics Ltd. (BBL), a … www.bioconbiologics.com.
About Biocon Limited
Biocon Limited, publicly listed in 2004 …
-
Biocon Biologics Secures U.S. Market Entry Timeline for Yesafili, Interchangeable Biosimilar to Eylea
16 Apr 2025 17:41 GMT
… Biocon Biologics and Regeneron includes the dismissal of ongoing litigation concerning patent … US11084865 (‘865 patent) at the … the path for Biocon Biologics to be … amp; Managing Director of Biocon Biologics.
“As the first …
-
Biocon Biologics secures market entry date for Eylea biosimilar
16 Apr 2025 14:50 GMT
… ;s Eylea (aflibercept).
Biocon Biologics and Regeneron executed the … the Federal Circuit of patent US11084865 and the pending … confidential.
[Read more: Biocon Biologics, Civica collaborate to … May 2024. Additionally, Biocon Biologics secured a settlement …
-
Biocon settles eye disease biosimilar dispute with US biotech Regeneron
16 Apr 2025 12:33 GMT
… Indian drug maker Biocon’s biosimilars arm Biocon Biologics has announced … the pending appeal of patent at the United States … CEO & Managing Director, Biocon Biologics, commented.
While the … the announced settlement allows Biocon to commercialize Yesafili in …
-
Biocon achieves settlement agreement with Regeneron to launch aflibercept biosimilar, Yesafili, in the US
15 Apr 2025 23:36 GMT
… the Federal Circuit of patent US11084865 and the … and managing director at Biocon Biologics, commented on the … biosimilar from Biocon in May 2024. Biocon also previously … myopic choroidal neovascularization.
Reference
Biocon Biologics secures market entry …
-
Biocon, Regeneron settle to launch aflibercept biosimilar, Yesafili in the US
15 Apr 2025 22:09 GMT
… the Federal Circuit (USCAFC) of patent US11084865 and the pending litigation … approved the biosimilar from Biocon in May 2024. Biocon also previously secured … choroidal neovascularization (myopic CNV).
References:
Biocon Biologics secures market entry date …
-
Biocon Biologics secures market entry date for ophthalmology drug Yesafili in US
15 Apr 2025 11:15 GMT
… its reference product EYLEA (aflibercept).
Biocon Biologics and Regeneron executed the … Federal Circuit (USCAFC) of patent US11084865 (‘865 patent) and the pending litigation … in May 2024.
Additionally, Biocon Biologics secured a settlement agreement …
-
Biocon Biologics secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
15 Apr 2025 11:14 GMT
… reference product EYLEA® (aflibercept).
Biocon Biologics and Regeneron executed the … Circuit (USCAFC) of patent US11084865 ('865 patent) and the pending … .
Source : Equity Bulls
Keywords
Biocon
INE376G01013
BioconBiologics
MarketEntryDate
US
Yesafili …
-
Biocon share price jumps 4% as subsidiary secures market entry for Yesafili in US
15 Apr 2025 10:54 GMT
… reference product EYLEA (aflibercept).
Biocon Biologics and Regeneron executed … Circuit (USCAFC) of a patent and the pending litigation … May 2024. Additionally, Biocon Biologics secured a settlement … July 1, 2025, Biocon said.
Biocon share price has gained …
-
Biocon Biologics secures market entry date for Yesafili, an interchangeable biosimilar to Eylea, in US
15 Apr 2025 06:30 GMT
… Eylea (aflibercept).
The Bengaluru-based Biocon Biologics and Regeneron executed the … Federal Circuit (USCAFC) of patent US11084865 (865 patent) and the pending litigation … in May 2024. Additionally, Biocon Biologics secured a settlement agreement …
About
© 1995-2025